This study looked for a plasma marker for depression and treatment efficacy sertraline. Yet, what does this mean for pathophysiology of depression taking into account that, to my knowledge blood-brain barrier sets a distribution separation between peripheral and central compartments of proteins and peptides.
Article Assessment of non-BDNF neurotrophins and GDNF levels after d...
Perhaps you find something useful in these papers:
Biochim Biophys Acta. Oct 2008; 1782(10): 549–558.
Published online Aug 7, 2008. doi: 10.1016/j.bbadis.2008.07.008
Peptides and Proteins in Plasma and Cerebrospinal Fluid as Biomarkers for the Prediction, Diagnosis, and Monitoring of Therapeutic Efficacy of Alzheimer’s Disease. Christopher D. Aluise, Renã A. Sowell, and D. Allan Butterfield
Nat Neurosci. Apr 2013; 16(4): 407–415.
EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons. Dirk Puehringer et al.
Curr Neurovasc Res. 2009 Feb;6(1):42-53.
Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Islam O, Loo TX, Heese K.
Histol Histopathol. 2010 Feb;25(2):237-58.
BDNF function and intracellular signaling in neurons.
Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H.
"Sertraline is primarily a serotonin reuptake inhibitor (SRI) with a binding affinity towards the serotonin transporter of Ki=2.0μM.Therapeutic doses of sertraline (25–200 mg/day) taken by patients for four weeks resulted in 80–90% inhibition of serotonin transporter (SERT) in striatum as measured by positron emission tomography. A daily 9 mg dose was sufficient to inhibit 50% of SERT.
Sertraline is also a dopamine reuptake inhibitor, (
- Badges
- Science topic